Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5‐Fluorouracil/ <i>Levo</i> ‐Leucovorin for Pancreatic Cancer
Concomitant administration of Levo-LV with nal-IRI may not increase adverse events or impact efficacy compared to sequential administration.
Authors
- Hiroshi Ishikawa (ORCID: https://orcid.org/0000-0003-1116-6885)
- Michihiro Shino
- Junya Sato (ORCID: https://orcid.org/0000-0002-2478-0190)
- Takeshi Kawakami
- Keita P. Mori (ORCID: https://orcid.org/0000-0001-5468-3634)
- Akane Wakabayashi
- Rei Tanaka
- Yurie Fukumuro
Institutions
- Shizuoka Cancer Center (JP)
- Shonan University of Medical Sciences (JP)
Publication Details
- Journal
- Cancer Reports
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cnr2.70485
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00